Physician

Alan Martin, M.D.

According to 2025 Medicare claims, Alan Martin, M.D. (NPI: 1083677017) practices rheumatology in the Tulsa, OK market, with the plurality of this provider's patient population coming from Tulsa, OK. This provider's primary affiliated billing organization is TULSA BONE & JOINT ASSOCIATES PC (NPI: 1154373132; TIN: 731551429) and primary practice location at 74146-5826. Martin is affiliated with the Honest MSSP of Michigan LLC (ACO ID: A5616), participating under the MSSP model.

Martin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 330 traditional Medicare patients, billed 164,960 HCPCS/CPT codes, and received $1,732,975 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,647 prescription claims across 386 beneficiaries totaling $1,907,639 in drug costs, led by Enbrel Sureclick (Etanercept). DME data shows 12 claims. Open Payments data shows 155 records totaling $2,908. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $653,944 to $1,907,639. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $0 to $24,318.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	460	39,479	$1,304,949
2016	471	45,687	$1,346,486
2017	541	58,280	$1,458,910
2018	573	63,273	$1,730,948
2019	562	82,931	$1,700,335
2020	501	86,118	$1,879,719
2021	455	112,582	$1,741,077
2022	433	160,658	$2,002,742
2023	382	180,897	$1,873,856
2024	330	164,960	$1,732,975

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	408	2,948	$653,944
2016	411	2,876	$746,477
2017	428	3,280	$1,134,081
2018	465	3,402	$1,068,089
2019	430	3,161	$1,205,048
2020	402	2,878	$1,153,080
2021	397	2,661	$1,439,527
2022	400	2,662	$1,643,301
2023	383	2,578	$1,740,864
2024	386	2,647	$1,907,639

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	12	$10,657
2022	N/R	12	$19,254
2023	N/R	12	$23,885
2024	N/R	12	$24,318

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	98	163	$102
96413	Administration of chemotherapy into vein, 1 hour or less	50	277	$81
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	285	667	$81
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	69	438	$41
J1602	Injection, golimumab, 1 mg, for intravenous use	50	46,400	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	61	1,708	$459,865
Enbrel	Etanercept	52	1,568	$421,724
Humira(Cf)	Adalimumab	11	588	$194,785
Xeljanz	Tofacitinib Citrate	30	900	$166,484
Humira(Cf) Pen	Adalimumab	25	700	$162,659

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	N/R	12	$24,318

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	155	$2,908	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alan Martin, M.D.?

Tedicare shows public-source Medicare data for Alan Martin, M.D. (NPI 1083677017), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alan Martin, M.D. have ACO affiliation data?

Alan Martin, M.D. is shown with ACO affiliation data for Honest MSSP of Michigan LLC (MSSP, ACO ID A5616).

What billing organization is linked to Alan Martin, M.D.?

Alan Martin, M.D. is linked to TULSA BONE & JOINT ASSOCIATES PC (billing NPI 1154373132) in the available physician profile data.

Does Alan Martin, M.D. have Open Payments data?

Alan Martin, M.D. has 155 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.